Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 3, 2013, Pages 464-472

  Kojima, Naoki ^a,b   Williams, Jan M ^a   Takahashi, Teisuke ^a,b   Miyata, Noriyuki ^a,c   Roman, Richard J ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LISINOPRIL; LUSEOGLIFLOZIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; FOOD INTAKE; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY TUBULE NECROSIS; LONG TERM CARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; WEIGHT REDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EATING; GLOMERULAR FILTRATION RATE; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY; LISINOPRIL; MALE; PROTEINURIA; RATS; RENAL CIRCULATION; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL;

EID: 84878060305     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.203869     Document Type: Article

References (27)

1. Anderson PW, Zhang XY, Tian J, Correale JD, Xi XP, Yang D, Graf K, Law RE, and Hsueh WA (1996) Insulin and angiotensin II are additive in stimulating TGFbeta 1 and matrix mRNAs in mesangial cells. Kidney Int 50:745-753.
2. Bailey CJ, Gross JL, Pieters A, Bastien A, and List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet 375:2223-2233.
3. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, and Cao Z (2001) Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 44:874-877.
4. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, and MacAllister RJ (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and metaanalysis. Lancet 366:2026-2033.
5. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, and Whaley JM (2008) Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57:1723-1729.
6. Jones SC, Saunders HJ, and Pollock CA (1999) High glucose increases growth and collagen synthesis in cultured human tubulointerstitial cells. Diabet Med 16: 932-938.
7. Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, Arai M, Kawakita Y, Fukasawa Y, Iida I, Hagima N, Takeuchi H, and Chino Y, et al. (2010) (1S)-1,5-anhydro-1-[5- (4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 53:3247-3261.
8. Kojima N, Williams JM, Takahasi T, Miyata N, and Roman RJ (2012) Renoprotective effects of SGLT2 inhibitor, Luseogliflozin, on the progression of diabetic nephropathy in T2DN rats (Abstract). Abstracts of High Blood Pressure Research 2012 Scientific Sessions, Sept 19-22, 2012, Washington, DC. Abstract 221, page 91.
9. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, and Chaithiraphan S, et al.; ONTARGET investigators (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372:547-553.
10. Nobrega MA, Fleming S, Roman RJ, Shiozawa M, Schlick N, Lazar J, and Jacob HJ (2004) Initial characterization of a rat model of diabetic nephropathy. Diabetes 53: 735-742.
11. Nobrega MA, Solberg Woods LC, Fleming S, and Jacob HJ (2009) Distinct genetic regulation of progression of diabetes and renal disease in the Goto-Kakizaki rat. Physiol Genomics 39:38-46.
12. Ohkubo Y, Kishikawa H, Araki E,Miyata T, Isami S,Motoyoshi S, Kojima Y, Furuyoshi N, and Shichiri M (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117.
13. Phillips AO, Steadman R, Morrisey K, Martin J, Eynstone L, and Williams JD (1997) Exposure of human renal proximal tubular cells to glucose leads to accumulation of type IV collagen and fibronectin by decreased degradation. Kidney Int 52:973-984.
14. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, and Brown J (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427-3434.
15. Remuzzi G, Macia M, and Ruggenenti P (2006) Prevention and treatment of diabetic renal disease in type 2 diabetes: The BENEDICT study. J Am Soc Nephrol 17(4, Suppl 2)S90-S97.
16. SalehMA, Boesen EI, Pollock JS, Savin VJ, and Pollock DM (2011) Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocininduced rat model of diabetes. Diabetologia 54:979-988.
17. Sarafidis PA and Ruilope LM (2006) Insulin resistance, hyperinsulinemia, and renal injury: Mechanisms and implications. Am J Nephrol 26:232-244.
18. Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, Takeda M, Yata T, Kawai M, and Fukuzawa T, et al. (2012) Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 341:692-701.
19. Tabatabai NM, Sharma M, Blumenthal SS, and Petering DH (2009) Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract 83:e27-e30.
20. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, and Tomiyama H, et al. (2012) Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide- induced mildly diabetic mice. J Pharmacol Sci 120:36-44.
21. Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, and Singh P (2012) Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302:R75-R83.
22. Ueda H, Ishimura E, Shoji T, Emoto M, Morioka T, Matsumoto N, Fukumoto S, Miki T, Inaba M, and Nishizawa Y (2003) Factors affecting progression of renal failure in patients with type 2 diabetes. Diabetes Care 26:1530-1534.
23. US Renal Data System (2012) 2011 USRDS Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
24. Vestri S, Okamoto MM, de Freitas HS, Aparecida Dos Santos R, Nunes MT, Morimatsu M, Heimann JC, andMachado UF (2001) Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 182:105-112.
25. Williams JM, Zhang J, North P, Lacy S, Yakes M, Dahly-Vernon A, and Roman RJ (2011) Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. Am J Physiol Renal Physiol 300:F983-F998.
26. Yamamoto K, Uchida S, Kitano K, Fukuhara N, Okumura-Kitajima L, Gunji E, Kozakai A, Tomoike H, Kojima N, and Asami J, et al. (2011) TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 164:181-191.
27. Ziyadeh FN, Snipes ER, Watanabe M, Alvarez RJ, Goldfarb S, and Haverty TP (1990) High glucose induces cell hypertrophy and stimulates collagen gene transcription in proximal tubule. Am J Physiol 259:F704-F714.